LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
| Autor: | Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J.A., Janjigian, Y.Y. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1191-S1191 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|